Bioceres Crop Solutions Corp. (BIOX) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2025
Loading P/E history...
BIOX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Bioceres Crop Solutions Corp. (BIOX) trades at a price-to-earnings ratio of -0.6x, with a stock price of $0.47 and trailing twelve-month earnings per share of $-0.83.
The current P/E is 100% below its 5-year average of 152.1x. Over the past five years, BIOX's P/E has ranged from a low of 39.1x to a high of 472.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Basic Materials sector median P/E of 23.4x, BIOX trades at a 102% discount to its sector peers. The sector includes 125 companies with P/E ratios ranging from 2.0x to 144.2x.
Relative to the broader market, BIOX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BIOX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BIOX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $53B | 49.4 | 4.14 | +23% | |
| $8B | 25.5 | 1.11 | -25% | |
| $157B | 31.4 | 1.92 | +0% | |
| $18B | 13.2 | 0.30Best | +33% | |
| $7B | 5.9Lowest | 0.34 | +605%Best | |
| $33B | 14.4 | 0.35 | +249% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BIOX Historical P/E Data (2018–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | $6.08 | $0.03 | 210.4x | +38% | |
| FY2025 Q1 | Mon Sep 30 2024 00:00:00 GM | $7.87 | $0.03 | 271.4x | +78% |
| FY2024 Q4 | Sun Jun 30 2024 00:00:00 GM | $11.21 | $0.04 | 258.9x | +70% |
| FY2024 Q3 | Sun Mar 31 2024 00:00:00 GM | $12.66 | $0.04 | 305.8x | +101% |
| FY2024 Q2 | Sun Dec 31 2023 00:00:00 GM | $13.73 | $0.35 | 39.1x | -74% |
| FY2024 Q1 | Sat Sep 30 2023 00:00:00 GM | $11.29 | $0.22 | 51.4x | -66% |
| FY2023 Q4 | Fri Jun 30 2023 00:00:00 GM | $13.36 | $0.30 | 44.4x | -71% |
| FY2023 Q3 | Fri Mar 31 2023 00:00:00 GM | $11.61 | $0.22 | 53.2x | -65% |
| FY2022 Q2 | Fri Dec 31 2021 00:00:00 GM | $14.14 | $0.09 | 152.4x | +0% |
| FY2022 Q1 | $13.50 | $0.03 | 472.0x | +210% | |
| FY2021 Q1 | Wed Sep 30 2020 00:00:00 GM | $5.36 | $0.09 | 59.4x | -61% |
| FY2020 Q4 | $6.06 | $0.08 | 75.5x | -50% |
Average P/E for displayed period: 152.1x
See BIOX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIOX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIOX vs LIN
Side-by-side business, growth, and profitability comparison vs Linde plc.
Start ComparisonBIOX — Frequently Asked Questions
Quick answers to the most common questions about buying BIOX stock.
Is BIOX stock overvalued or undervalued?
BIOX trades at -0.6x P/E, below its 5-year average of 152.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BIOX's valuation compare to peers?
Bioceres Crop Solutions Corp. P/E of -0.6x compares to sector median of 23.4x. The discount suggests lower growth expectations or higher risk.
What is BIOX's PEG ratio?
BIOX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2025.